Reported 2 days ago
Piper Sandler analyst Yasmeen Rahimi has maintained a Buy rating on Cytokinetics (NASDAQ:CYTK) with a price target of $107 effective June 4. Despite a recent downgrade by JPMorgan, the firm continues to view aficamten, a drug for obstructive hypertrophic cardiomyopathy, as having strong potential due to its unique profile compared to competitors. Cytokinetics focuses on developing muscle inhibitors aimed at improving muscle function.
Source: YAHOO
Reported 2 days ago
H.C. Wainwright analyst Patrick Trucchio reaffirmed a Buy rating for Beam Therapeutics Inc. (NASDAQ:BEAM) with a price target of $80, citing the company's promising gene editing pipeline, particularly their base editing therapies. Beam is advancing various programs for genetic diseases, with significant milestones anticipated, positioning it well for future growth in the biotechnology sector.
Source: YAHOO
Reported 2 days ago
H.C. Wainwright analyst Mitchell Kapoor has reiterated a Buy rating for Legend Biotech Corporation (NASDAQ: LEGN), setting a price target of $75. The positive outlook is driven by the company's CARVYKTI treatment, recently approved by the FDA without a risk evaluation strategy, which is expected to enhance its market launch. Despite acknowledging alternatives, the analyst emphasizes the company's potential in the oncology sector.
Source: YAHOO
Reported 2 days ago
Morgan Stanley has raised its price target for CG Oncology, Inc. (NASDAQ:CGON) to $56 from $52 while retaining an Overweight rating. The firm noted that despite recent approvals in the non-muscle invasive bladder cancer market, there remains ample opportunity for multiple competitors. CG Oncology's product, cretostimogene, distinguishes itself with favorable safety data and durability, suggesting strong potential in the market.
Source: YAHOO
Reported 2 days ago
Citizens JMP has reiterated its Buy rating on Dynavax Technologies Corporation (NASDAQ:DVAX), setting a price target of $31. The biopharmaceutical company reported record net product revenue for its hepatitis B vaccine, HEPLISAV-B, at $65 million in fiscal Q1 2025, marking a 36% year-over-year increase. Furthermore, Dynavax is advancing new vaccine programs for pandemic influenza and Lyme disease, with clinical developments expected in the next few years.
Source: YAHOO
Reported 2 days ago
LifeSci Capital analyst Sam Slutsky has reaffirmed a Buy rating for Immunovant, Inc. (NASDAQ:IMVT) with a price target of $50, citing the significant market potential for its drug IMVT-1402, targeted at treating Graves’ disease. This condition affects around one million patients in the US, and existing treatments often fall short. The analyst emphasized IMVT-1402's novel approach in reducing pathogenic IgG autoantibodies, indicating strong demand for such targeted therapies. With ongoing trials supporting their optimistic view, Immunovant aims to address substantial unmet medical needs in autoimmune diseases.
Source: YAHOO
Reported 2 days ago
POSCO Holdings has announced its plan to construct a pilot lithium processing plant in Green River City, Utah, in collaboration with Australia's Anson Resources. This initiative aims to enhance the supply chain for electric vehicle (EV) batteries and reduce dependence on Chinese suppliers, following new US import restrictions. The plant will utilize POSCO's patented Direct Lithium Extraction technology to evaluate its commercial viability, marking a significant milestone as it will be the first instance of a South Korean company directly producing lithium in North America.
Source: YAHOO
Reported 2 days ago
Summit Therapeutics Inc. is reportedly in talks with AstraZeneca regarding a potential $15 billion licensing agreement for the lung cancer drug ivonescimab. While negotiations are ongoing, the deal could include a substantial upfront payment and future milestones, although it may not be finalized, as Summit might opt for a different partnership. Summit acquired rights to ivonescimab through a $5 billion deal with Akeso in December 2022.
Source: YAHOO
Reported 2 days ago
Globalstar Inc. has started a significant expansion of its C-3 satellite system by installing the Clifton-8 tracking antenna in Texas, marking the beginning of an upgrade to its ground infrastructure for the Extended Mobile Satellite Services Network. This installation, which is the first of five new antennas planned for the Clifton facility, is part of a larger initiative to deploy over 90 antennas across approximately 35 ground stations worldwide.
Source: YAHOO
Reported 2 days ago
Citius Pharmaceuticals Inc. is preparing for the commercial launch of LYMPHIR, an FDA-approved immunotherapy for cutaneous T-cell lymphoma, targeting a release in Q2 2025. The company has completed manufacturing and established distribution agreements to ensure ample supply. A comprehensive marketing strategy is in place to support the product's introduction, leveraging GenAI models for key account engagement and developing educational resources for healthcare providers and patients. LYMPHIR's presence in clinical guidelines and reimbursement strategies positions it well for market entry.
Source: YAHOO
Reported 2 days ago
UroGen Pharma has received FDA approval for ZUSDURI, an innovative treatment for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer. This first-of-its-kind medication, previously known as UGN-102, delivers mitomycin via a sterile hydrogel using sustained-release technology. The approval comes after encouraging results from the Phase 3 ENVISION trial, which showed that 78% of patients achieved a complete response at three months, with a notable majority maintaining this response after 12 months.
Source: YAHOO
Reported 2 days ago
Prime Medicine Inc. is restructuring its operations to concentrate on in vivo programs for genetic liver diseases, including Wilson’s Disease and Alpha-1 Antitrypsin Deficiency, after reporting positive results from its clinical trial for PM359 in Chronic Granulomatous Disease. The company plans to file investigational drug applications for its liver disease programs by 2026, while seeking external options for further development of PM359.
Source: YAHOO
Reported 2 days ago
ImmunoPrecise Antibodies Ltd. has made a significant breakthrough with its LENSai platform, achieving high accuracy in epitope mapping through the use of its proprietary HYFT technology. A benchmark study demonstrated LENSai's capability to predict antibody binding sites on previously unseen targets with impressive accuracy, mirroring results from its training data. This innovative approach enables rapid analysis using just digital sequences, in stark contrast to traditional methods that are time-consuming and resource-heavy. The company is actively expanding partnerships with major pharma and biotech firms, highlighting its potential in the biotech industry.
Source: YAHOO
Reported 2 days ago
Newegg Commerce Inc. has launched its 11th annual FantasTech Sale, running from July 7 to July 13, featuring thousands of deals across various electronics categories. For the first time, the FantasTech Price Protection program has been expanded to include select eligible items from previous sales, offering refunds on price differences until July 13. Customers will receive refunds without the need to track prices, and confirmations will be emailed once processed.
Source: YAHOO
Reported 2 days ago
Peloton has launched 'Peloton Repowered,' a peer-to-peer resale marketplace for its used fitness equipment and accessories, currently in beta and available only in the Boston, New York City, and Washington, D.C. areas. Sellers will receive 70% of the sale price and can earn discounts on new equipment, while buyers benefit from a reduced activation fee. The platform is developed in partnership with resale company Archive, which has raised significant funding recently.
Source: YAHOO
Reported 2 days ago
In May 2025, Patterson-UTI Energy Inc. reported an average of 103 drilling rigs operating in the US. This figure reflects the company's ongoing drilling activities and highlights its position in the energy sector. The average number of rigs operating over the two months leading up to May was 106. Patterson-UTI continues to provide monthly updates on its drilling rig activity, emphasizing that the number of operating rigs is just one factor influencing the company’s overall financial performance.
Source: YAHOO
Reported 2 days ago
BridgeBio Pharma Inc. raised $300 million by partially monetizing its European royalty rights for BEYONTTRA, an oral treatment for transthyretin amyloidosis. The financing, arranged with HealthCare Royalty and Blue Owl Capital, provides upfront capital by giving away 60% of royalties on the first $500 million of annual sales in Europe. This deal aims to strengthen BridgeBio's financial position and support its ongoing projects, including the launch of Attruby in the US.
Source: YAHOO
Reported 2 days ago
Omnicom Group and Achieve Life Sciences have entered a strategic partnership to spearhead the US launch of cytisinicline, a new treatment for nicotine dependence. This collaboration aims to leverage AI technology and a data-driven approach for effective marketing and engagement with healthcare professionals and patients. With a unified team from various specialized agencies, the project seeks to revolutionize biopharma commercialization.
Source: YAHOO
Reported 2 days ago
Nuvalent Inc. has announced positive pivotal results from its ARROS-1 Phase 1/2 trial for zidesamtinib, a new treatment for patients with advanced ROS1-positive non-small cell lung cancer. The FDA has agreed to consider an NDA submission under its Real-Time Oncology Review program, allowing for accelerated evaluation. A rolling NDA submission is planned for July, with hopes to complete it by Q3 2025.
Source: YAHOO
Reported 2 days ago
Jazz Pharmaceuticals has received conditional marketing authorization from the European Commission for its bispecific antibody Ziihera (zanidatamab) to treat advanced biliary tract cancer in adults who have previously undergone systemic therapy. This approval applies to all EU member states and is based on Phase IIb clinical trial data. Further confirmation of clinical benefits is awaited from an ongoing Phase III trial.
Source: YAHOO
Reported 2 days ago
BioCryst Pharmaceuticals has finalized a deal to sell its European ORLADEYO business to Neopharmed Gentili for up to $264 million, including a $250 million upfront payment. The transaction, expected to close by early October, will help BioCryst eliminate approximately $70 million in future interest costs on its term debt and improve its cash position significantly by the end of 2027. The sale also includes the transfer of BioCryst's European organization, potentially yielding considerable annual operational savings.
Source: YAHOO
Reported 2 days ago
Shift4 Payments has partnered with UATP, a global payment network, to enhance payment solutions for the travel industry by integrating UATP's patented technology. This collaboration aims to improve the payment infrastructure for airlines and travel agencies worldwide, facilitating corporate travel payments and expanding sales opportunities in the global market.
Source: YAHOO
Reported 2 days ago
Hims & Hers Health Inc. has announced its acquisition of ZAVA, a prominent digital health platform in Europe, enhancing its international presence. This strategic move aims to launch a branded offering in the European market, providing personalized digital health services in areas like dermatology, weight loss, sexual health, and mental health, with local language support. The integration is expected to begin by 2026, leveraging ZAVA's existing customer base and consultation capabilities.
Source: YAHOO
Reported 2 days ago
Coherent Corp. has introduced its new ACE FL series, a thulium fiber laser designed for advanced medical treatments, particularly focusing on lithotripsy and benign prostatic hyperplasia (BPH). This innovative system offers enhanced efficiency and precision compared to older laser technologies, with features that facilitate OEM integration and improved energy performance. The ACE FL will be showcased at the LASER World of Photonics Munich 2025 event.
Source: YAHOO
Reported 2 days ago
HubSpot has partnered with MatrixPoint by including them in its Solutions Partner Program, aiming to improve customer engagement and broaden CRM expertise. This collaboration will enable MatrixPoint, a media consultancy focused on marketing transformation, to enhance its CRM practices and help clients utilize customer data more effectively for personalized interactions.
Source: YAHOO